Corus Pharma was acquired by Gilead Sciences for $365 million
On Aug. 11, 2006, Gilead Sciences announced that it had completed its acquisition of Corus Pharma for $365 million.
Gilead retained the Corus’ Seattle-based operations, establishing a center of expertise in respiratory therapeutics.
Tags:
Source: Gilead Sciences
Credit:
